| scholarly article | Q13442814 |
| P356 | DOI | 10.1212/WNL.43.11.2245 |
| P698 | PubMed publication ID | 8232937 |
| P50 | author | Barbara Cohen | Q52555836 |
| Eric N Miller | Q56566453 | ||
| P2093 | author name string | N M Graham | |
| J T Becker | |||
| J C McArthur | |||
| L P Jacobson | |||
| O A Selnes | |||
| D R Hoover | |||
| H Bacellar | |||
| J H McArthur | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV/AIDS | Q12199 |
| dementia | Q83030 | ||
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 2245-2252 | |
| P577 | publication date | 1993-11-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study | |
| P478 | volume | 43 |
| Q40404713 | A Longitudinal Analysis of the Impact of Physical Activity on Neurocognitive Functioning Among HIV-Infected Adults |
| Q35949256 | A comparison of two post-processing analysis methods to quantify cerebral metabolites measured via proton magnetic resonance spectroscopy in HIV disease |
| Q47096317 | A miRNA Signature for Cognitive Deficits and Alcohol Use Disorder in Persons Living with HIV/AIDS. |
| Q46391907 | A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia |
| Q35993860 | A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings |
| Q36363603 | A neuropsychiatrist's perspective on selected dermatoses |
| Q48317783 | AIDS and psychiatry, revisited |
| Q34777672 | AIDS dementia |
| Q33750280 | AIDS dementia complex |
| Q82029761 | AIDS dementia complex |
| Q42478988 | AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations |
| Q35015470 | AZT myopathy and HIV-1 polymyositis: one disease or two? |
| Q35587294 | Adiponectin and interleukin-6, but not adipose tissue, are associated with worse neurocognitive function in HIV-infected men |
| Q34466555 | Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality |
| Q46966972 | Altered P-glycoprotein expression in AIDS patients with HIV encephalitis |
| Q43540062 | Amelioration of neurotoxic effects of HIV envelope protein gp120 by fibroblast growth factor: a strategy for neuroprotection |
| Q39581093 | An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus |
| Q35966034 | An update on the neuropathology of HIV in the HAART era. |
| Q36654580 | Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era |
| Q90525044 | Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study |
| Q37144508 | Animal models of retroviral encephalopathies: feline model |
| Q90541942 | Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study |
| Q34459372 | Antiretroviral treatment of central nervous system HIV-1 infection: a review |
| Q28267535 | Apoptotic death of striatal neurons induced by human immunodeficiency virus-1 Tat and gp120: Differential involvement of caspase-3 and endonuclease G |
| Q37015514 | Assessment of neuroAIDS in the international setting |
| Q35103153 | Association of platelet-derived growth factor-B chain with simian human immunodeficiency virus encephalitis |
| Q42429157 | Astrocytic expression of HIV-1 Nef impairs spatial and recognition memory |
| Q33987146 | Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline |
| Q35624697 | Autophagy in dementias |
| Q36511540 | Bone marrow diffusion measures correlate with dementia severity in HIV patients |
| Q33614467 | Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals |
| Q36831291 | CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain |
| Q37600700 | CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. |
| Q48714127 | CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection |
| Q34125560 | Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. |
| Q45732507 | Caspase cascades in human immunodeficiency virus-associated neurodegeneration. |
| Q36068289 | Cell death in HIV dementia |
| Q48919955 | Cell death mechanisms in HIV-associated dementia: the involvement of syncytia |
| Q34398632 | Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system |
| Q36376213 | Central nervous system viral invasion and inflammation during acute HIV infection |
| Q33587212 | Cerebrospinal fluid (CSF) biomarkers of iron status are associated with CSF viral load, antiretroviral therapy, and demographic factors in HIV-infected adults |
| Q24814874 | Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment |
| Q45783177 | Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) p24 antigen levels in HIV-1-related dementia |
| Q41528498 | Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients |
| Q35126422 | Changing patterns in the neuropathogenesis of HIV during the HAART era. |
| Q90511157 | Characteristics of motor dysfunction in longstanding HIV |
| Q33782833 | Chemokine receptor utilization by human immunodeficiency virus type 1 isolates that replicate in microglia |
| Q42875320 | Chronic cocaine exposure in the SCID mouse model of HIV encephalitis |
| Q44367684 | Clinical features, diagnosis and treatment of HIV-induced neuropsychiatric disorders |
| Q37300421 | Cocaine and HIV-1 interplay in CNS: cellular and molecular mechanisms |
| Q51967167 | Cognitive Effects of HIV-1 Infection. |
| Q97073462 | Cognitive disorders in people living with HIV |
| Q40431761 | Cognitive function in early HIV infection |
| Q48323194 | Cognitive impairment in HIV infection is associated with MRI and CSF pattern of neurodegeneration |
| Q35057500 | Cognitive impairment in patients with AIDS - prevalence and severity |
| Q22252615 | Cognitive neuropsychology of HIV-associated neurocognitive disorders |
| Q36376672 | Cohort Profile: Recruitment cohorts in the neuropsychological substudy of the Multicenter AIDS Cohort Study |
| Q45730280 | Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City |
| Q34934375 | Comorbidity of depression with other medical diseases in the elderly |
| Q34103216 | Comparison of scales to evaluate the progression of HIV-associated neurocognitive disorder |
| Q36294152 | Comparison of the Minimental State Examination Scale and the International HIV Dementia Scale in Assessing Cognitive Function in Nigerian HIV Patients on Antiretroviral Therapy |
| Q34069128 | Consensus statement: anemia in HIV infection--current trends, treatment options, and practice strategies. Anemia in HIV Working Group |
| Q33647684 | Cooperative induction of CXCL10 involves NADPH oxidase: Implications for HIV dementia. |
| Q30478136 | Correlation of acute humoral response with brain virus burden and survival time in pig-tailed macaques infected with the neurovirulent simian immunodeficiency virus SIVsmmFGb |
| Q45421792 | Critical implication of the (70-96) domain of human immunodeficiency virus type 1 Vpr protein in apoptosis of primary rat cortical and striatal neurons |
| Q36623074 | Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences |
| Q36628324 | Diffusion tensor imaging of subcortical brain injury in patients infected with human immunodeficiency virus |
| Q71810257 | Distinct HIV-1 env Sequences Are Associated with Neurotropism and Neurovirulence |
| Q37719543 | Does highly active antiretroviral therapy improve neurocognitive function? A systematic review |
| Q34302241 | Dysregulation of macrophage-secreted cathepsin B contributes to HIV-1-linked neuronal apoptosis |
| Q37111890 | Early detection of neuropathophysiology using diffusion-weighted magnetic resonance imaging in asymptomatic cats with feline immunodeficiency viral infection |
| Q36993831 | Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders |
| Q36902304 | Effects of the HIV-1 viral protein TAT on central neurotransmission: role of group I metabotropic glutamate receptors |
| Q34400263 | Ethanol potentiates HIV-1 gp120-induced apoptosis in human neurons via both the death receptor and NMDA receptor pathways |
| Q36318621 | Evidence of CNS impairment in HIV infection: clinical, neuropsychological, EEG, and MRI/MRS study. |
| Q36302081 | Experimental and potential future therapeutic approaches for HIV-1 associated dementia targeting receptors for chemokines, glutamate and erythropoietin |
| Q45625995 | Expression of chemokines by human fetal microglia after treatment with the human immunodeficiency virus type 1 protein Tat. |
| Q41466517 | Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial |
| Q28469174 | Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial |
| Q48678017 | Frequency and risk factors for HIV-associated neurocognitive disorder and depression in older individuals with HIV in northeastern Brazil |
| Q39154647 | Functional CXCR4 receptor development parallels sensitivity to HIV-1 gp120 in cultured rat astroglial cells but not in cultured rat cortical neurons |
| Q45735916 | Functional analyses of natural killer cells in macaques infected with neurovirulent simian immunodeficiency virus |
| Q35883770 | Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders |
| Q33605737 | Gene expression patterns associated with neurological disease in human HIV infection |
| Q53560523 | General paralysis of the insane and AIDS in old age psychiatry: epidemiology, clinical diagnosis, serology and ethics--the way forward. |
| Q40303021 | Genetic markers on HIV-1 gp120 C2-V3 region associated with the expression or absence of cognitive motor complex in HIV/AIDS. |
| Q37980665 | Genotypical diversity of HIV clades and central nervous system impairment |
| Q61807984 | Gut Microbiota Dysbiosis Is Not Independently Associated With Neurocognitive Impairment in People Living With HIV |
| Q34112360 | HERVs in neuropathogenesis. |
| Q41712400 | HIV 1-associated neurocognitive disorder: current epidemiology, pathogenesis, diagnosis and management |
| Q37180359 | HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study |
| Q53904491 | HIV Dementia. |
| Q58750745 | HIV Neuroinfection and Alzheimer's Disease: Similarities and Potential Links? |
| Q37015469 | HIV Preclinical-Clinical Therapeutics Research: central nervous system approaches |
| Q88795213 | HIV disease and diabetes interact to affect brain white matter hyperintensities and cognition |
| Q34343628 | HIV in the CNS: pathogenic relationships to systemic HIV disease and other CNS diseases |
| Q35063626 | HIV neuropathogenesis: a tight rope walk of innate immunity. |
| Q36203732 | HIV's double strike at the brain: neuronal toxicity and compromised neurogenesis |
| Q34573511 | HIV, dementia and antiretroviral drugs: 30 years of an epidemic |
| Q40456270 | HIV-1 Associated Dementia: Clinical Features and Pathogenesis |
| Q43716009 | HIV-1 LTR C/EBP binding site sequence configurations preferentially encountered in brain lead to enhanced C/EBP factor binding and increased LTR-specific activity |
| Q40048514 | HIV-1 TAT inhibits microglial phagocytosis of Abeta peptide. |
| Q35875211 | HIV-1 Tat-mediated neurotoxicity in retinal cells. |
| Q92539113 | HIV-1 and Compromised Adult Neurogenesis: Emerging Evidence for a New Paradigm of HAND Persistence |
| Q62489022 | HIV-1 and TB Co-infection in Multinational Resource Limited Settings: Increased neurological dysfunction |
| Q37418815 | HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches |
| Q43251339 | HIV-1 clade-specific differences in the induction of neuropathogenesis |
| Q35856810 | HIV-1 effects on neuropsychological performance in a resource-limited country, Zambia |
| Q36098879 | HIV-1 infection and AIDS: consequences for the central nervous system |
| Q28474374 | HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination |
| Q40748861 | HIV-1 protein Tat reduces the glutamate-induced intracellular Ca2+ increase in cultured cortical astrocytes |
| Q36040759 | HIV-1, reactive oxygen species, and vascular complications |
| Q57300033 | HIV-1-Associated Neurocognitive Disorders: Is HLA-C Binding Stability to β-Microglobulin a Missing Piece of the Pathogenetic Puzzle? |
| Q30615171 | HIV-1-associated central nervous system dysfunction |
| Q30234305 | HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. |
| Q48871408 | HIV-Tat protein induces P-glycoprotein expression in brain microvascular endothelial cells |
| Q95796528 | HIV-associated cognitive impairment before and after the advent of combination therapy |
| Q42428657 | HIV-associated dementia: A diagnostic dilemma |
| Q34076133 | HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project |
| Q26766448 | HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment |
| Q38461834 | HIV-associated neurocognitive disorders |
| Q24631745 | HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors |
| Q37971469 | HIV-associated neurological disorders: a guide to pharmacotherapy |
| Q63408556 | HIV-induced neuroinflammation: impact of PAR1 and PAR2 processing by Furin |
| Q37899895 | HIV-related neurocognitive impairment--a review |
| Q40322637 | HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND). |
| Q64082246 | High prevalence of neurocognitive disorders observed among adult people living with HIV/AIDS in Southern Ethiopia: A cross-sectional study |
| Q33825647 | High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. |
| Q34406750 | Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort |
| Q46456152 | Highly active antiretroviral therapy and human immunodeficiency virus encephalitis |
| Q34987714 | Hippocampal MR spectroscopic abnormalities in a cohort of syphilitic patients with HIV and neurosyphilis infection |
| Q42439875 | Hippocampal synaptic dysfunction in a murine model of human immunodeficiency virus type 1 encephalitis |
| Q24794489 | Human CNS cultures exposed to HIV-1 gp120 reproduce dendritic injuries of HIV-1-associated dementia |
| Q38773755 | Human Immunodeficiency Virus Infection and Host Defense in the Lungs |
| Q30344068 | Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. |
| Q28256919 | Human immunodeficiency virus type 1 and its coat protein gp120 induce apoptosis and activate JNK and ERK mitogen-activated protein kinases in human neurons |
| Q45723766 | Human immunodeficiency virus type 1 envelope-mediated neuropathogenesis: targeted gene delivery by a Sindbis virus expression vector |
| Q36203752 | Human immunodeficiency virus type 1 genetic diversity in the nervous system: evolutionary epiphenomenon or disease determinant? |
| Q36804543 | Human immunodeficiency virus type 1 infection increases the in vivo capacity of peripheral monocytes to cross the blood-brain barrier into the brain and the in vivo sensitivity of the blood-brain barrier to disruption by lipopolysaccharide |
| Q40929005 | Human immunodeficiency virus type 1-related transient neurological deficits |
| Q35112016 | Human immunodeficiency virus-associated dementia: an evolving disease |
| Q35856188 | Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic |
| Q22252860 | Immune activation and inflammation in HIV-1 infection: causes and consequences |
| Q36866613 | Impact of HIV and aging on neuropsychological function |
| Q57831860 | Impact of current antiretroviral therapies on neuroAIDS |
| Q91760817 | Impaired insulin sensitivity is associated with worsening cognition in HIV-infected patients |
| Q33971765 | Implications of gliotransmission for the pharmacotherapy of CNS disorders |
| Q36379592 | Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study |
| Q48787192 | In vivo expression of proinflammatory cytokines in HIV encephalitis: an analysis of 11 autopsy cases |
| Q41089712 | In vivo modeling of HIV-1 mediated neurodegeneration. |
| Q36673268 | Increased in vivo activation of microglia and astrocytes in the brains of mice transgenic for an infectious R5 human immunodeficiency virus type 1 provirus and for CD4-specific expression of human cyclin T1 in response to stimulation by lipopolysacc |
| Q37492836 | Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment |
| Q45136860 | Inflammatory, oxidative and lipid perspectives on dementia in HIV-infected patients |
| Q34691336 | Inhibition of highly productive HIV-1 infection in T cells, primary human macrophages, microglia, and astrocytes by Sargassum fusiforme |
| Q41929326 | Interactions between human immunodeficiency virus (HIV)-1 Vpr expression and innate immunity influence neurovirulence |
| Q35996523 | Interactive Effects of Morphine on HIV Infection: Role in HIV-Associated Neurocognitive Disorder |
| Q42972738 | Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood-brain barrier dysfunction: implications for HIV-1-associated neurocognitive disorder |
| Q42125778 | Intra-cornu ammonis 1 administration of the human immunodeficiency virus-1 protein trans-activator of transcription exacerbates the ethanol withdrawal syndrome in rodents and activates N-methyl-D-aspartate glutamate receptors to produce persisting s |
| Q36659583 | Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons |
| Q47566977 | Lymphocyte-Dominant Encephalitis and Meningitis in Simian Immunodeficiency Virus-Infected Macaques Receiving Antiretroviral Therapy |
| Q37728093 | Macrophage signaling in HIV-1 infection |
| Q35098372 | Macrophage/microglial accumulation and proliferating cell nuclear antigen expression in the central nervous system in human immunodeficiency virus encephalopathy |
| Q35585229 | Management of Anemia of Chronic Disease in Patients with the Human Immunodeficiency Virus |
| Q28082139 | Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders |
| Q37015360 | Mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS. |
| Q38456160 | Memory for verbal information in individuals with HIV-associated dementia complex. HNRC Group |
| Q33566813 | Menin mediates Tat-induced neuronal apoptosis in brain frontal cortex of SIV-infected macaques and in Tat-treated cells |
| Q33799373 | Methamphetamine abuse, HIV infection, and neurotoxicity. |
| Q33985461 | Methamphetamine toxicity and its implications during HIV-1 infection. |
| Q39914267 | Methods to study monocyte migration induced by HIV-infected cells |
| Q34309557 | Microglia in HIV-associated neurological diseases |
| Q28305896 | Mitochondria influence Fas expression in gp120-induced apoptosis of neuronal cells |
| Q36155099 | Mitochondrial Haplogroup Influences Motor Function in Long-Term HIV-1-Infected Individuals |
| Q36550686 | Mixed membership trajectory models of cognitive impairment in the multicenter AIDS cohort study |
| Q40175740 | Modifications in acute phase and complement systems predict shifts in cognitive status of HIV-infected patients |
| Q37726311 | Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection |
| Q28751900 | Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies |
| Q45747428 | Morphological correlates of neurological dysfunction in macaques infected with neurovirulent simian immunodeficiency virus |
| Q52309275 | Motor function declines over time in human immunodeficiency virus and is associated with cerebrovascular disease, while HIV-associated neurocognitive disorder remains stable. |
| Q40241936 | Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV. |
| Q37522377 | NeuroAIDS: an evolving epidemic. |
| Q48637012 | NeuroAIDS: diagnosis and management |
| Q30445058 | Neurobehavioral alterations in HIV-1 transgenic rats: evidence for dopaminergic dysfunction |
| Q36072424 | Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid. |
| Q33827518 | Neurocognitive functioning in HIV-1 infection: effects of cerebrovascular risk factors and age |
| Q35033471 | Neurocognitive impairment associated with predominantly early stage HIV infection in Abuja, Nigeria |
| Q74401220 | Neurocognitive symptoms and impairment in an HIV community clinic |
| Q38960541 | Neuroepidemiology of HIV infection |
| Q82029714 | Neuroepidemiology of HIV/AIDS |
| Q37785813 | Neuroimmune Pharmacology of Neurodegenerative and Mental Diseases |
| Q34306701 | Neuroimmune and neurovirological aspects of human immunodeficiency virus infection |
| Q35177355 | Neuroimmunity and the blood-brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on neuroAIDS. |
| Q41240954 | Neurologic manifestations of HIV infection. |
| Q41728204 | Neurologic manifestations of HIV infection. Using imaging studies and antiviral therapy effectively |
| Q33590337 | Neurologic presentations of AIDS. |
| Q71264589 | Neurological complications of HIV infection |
| Q36234349 | Neurological complications of HIV infection. |
| Q34378701 | Neurological manifestations of HIV-1 infection in the HAART era. |
| Q35098067 | Neuronal apoptosis is mediated by CXCL10 overexpression in simian human immunodeficiency virus encephalitis |
| Q33785357 | Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients |
| Q45783777 | Neuronal density in the superior frontal and temporal gyri does not correlate with the degree of human immunodeficiency virus-associated dementia |
| Q35773841 | Neuronal pattern correlates with the severity of human immunodeficiency virus-associated dementia complex. Usefulness of spatial pattern analysis in clinicopathological studies |
| Q44305282 | Neuropathogenesis of Chimeric Simian/Human Immunodeficiency Virus infection In Pig‐tailed and Rhesus Macaques |
| Q27024914 | Neuropathogenesis of HIV-1-associated neurocognitive disorders: a possible involvement of D-serine |
| Q38414358 | Neuropathology of HAND With Suppressive Antiretroviral Therapy: Encephalitis and Neurodegeneration Reconsidered |
| Q82029838 | Neuropharmacology of HIV/AIDS |
| Q48799049 | Neurophysiological changes associated with psychiatric symptoms in HIV-infected individuals without AIDS. |
| Q57276245 | Neuroprotective effects of early antiretrovirals in vertical HIV infection |
| Q40518254 | Neuropsychiatric aspects of HIV infection |
| Q33827697 | Neuropsychiatric aspects of HIV infection among older adults |
| Q37213350 | Neuropsychological assessment of HIV-infected populations in international settings |
| Q34192399 | Neuroscience research in AIDS. |
| Q82354227 | Never too old |
| Q50051625 | No Neurocognitive Advantage for Immediate Antiretroviral Treatment in adults with greater than 500 CD4+ T Cell Counts. |
| Q33533941 | Normative scores for a brief neuropsychological battery for the detection of HIV-associated neurocognitive disorder (HAND) among South Africans |
| Q36335033 | Oxidative Stress Is Associated with Neuroinflammation in Animal Models of HIV-1 Tat Neurotoxicity |
| Q35112021 | Pathogenesis of Human Immunodeficiency Virus-Induced Neurological Disease |
| Q35890115 | Pathogenesis of simian immunodeficiency virus encephalitis: viral determinants of neurovirulence |
| Q34223078 | Pathways to neuronal injury and apoptosis in HIV-associated dementia. |
| Q34098796 | Pharmacological frontiers in the treatment of AIDS dementia |
| Q45418066 | Platelet decline: an early predictive hematologic marker of simian immunodeficiency virus central nervous system disease |
| Q37275841 | Platelet-derived growth factor protects neurons against gp120-mediated toxicity |
| Q40832033 | Postural reflexes in patients with HIV-1 infection |
| Q44903526 | Potential relationships between the presence of HIV, macrophages, and astrogliosis in SCID mice with HIV encephalitis |
| Q35699016 | Potentiation of Excitotoxicity in HIV-1 Associated Dementia and the Significance of Glutaminase |
| Q34098757 | Preclinical psychopharmacology of AIDS-associated dementia: lessons to be learned from the cognitive psychopharmacology of other dementias |
| Q47265639 | Preferential loss of large neocortical neurons during HIV infection: a study of the size distribution of neocortical neurons in the human brain |
| Q34402559 | Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. |
| Q34540563 | Progress in clinical neurosciences: The neuropathogenesis of HIV infection: host-virus interaction and the impact of therapy. |
| Q39921141 | Proinflammatory cytokines and HIV-1 synergistically enhance CXCL10 expression in human astrocytes. |
| Q45871733 | Protecting neurons from HIV-1 gp120-induced oxidant stress using both localized intracerebral and generalized intraventricular administration of antioxidant enzymes delivered by SV40-derived vectors |
| Q48930794 | Protection of human cerebral neurons from neurodegenerative insults by gene delivery of soluble tumor necrosis factor p75 receptor |
| Q34048920 | Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals |
| Q44132143 | Qualitative features of the memory deficit associated with hiv infection and AIDS: Cross-validation of a discriminant function classification scheme |
| Q43823530 | Reactive oxygen species generated by glia are responsible for neuron death induced by human immunodeficiency virus-glycoprotein 120 in vitro. |
| Q38633801 | Recent advances in the neurology of HIV infection |
| Q37553210 | Regulated exocytosis from astrocytes physiological and pathological related aspects. |
| Q59354554 | Relationship Between Brain Arterial Pathology and Neurocognitive Performance Among Individuals With Human Immunodeficiency Virus |
| Q43482054 | Relationship between apolipoprotein E4 genotype and white matter integrity in HIV-positive young adults in South Africa |
| Q45759163 | Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain |
| Q36797296 | Relationship between sex hormones and cognitive performance in men with substance use. |
| Q90226551 | Residency Training: Progressive gait difficulty and incontinence in a 40-year-old man with HIV |
| Q30452156 | Rhesus macaque model of chronic opiate dependence and neuro-AIDS: longitudinal assessment of auditory brainstem responses and visual evoked potentials |
| Q37001750 | Risk factors for HIV-associated neurocognitive disorders (HAND) in sub-Saharan Africa: the case of Yaoundé-Cameroon |
| Q36318432 | Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy |
| Q44633319 | Role of Na+/H+ exchangers, excitatory amino acid receptors and voltage-operated Ca2+ channels in human immunodeficiency virus type 1 gp120-mediated increases in intracellular Ca2+ in human neurons and astrocytes |
| Q26829535 | Role of Oxidative Stress in HIV-1-Associated Neurocognitive Disorder and Protection by Gene Delivery of Antioxidant Enzymes |
| Q38886489 | Role of microglial cells in selective replication of simian immunodeficiency virus genotypes in the brain |
| Q36516922 | Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia |
| Q35022621 | Role of trophic factors on neuroimmunity in neurodegenerative infectious diseases |
| Q37175209 | Roles of MCP-1 in development of HIV-dementia |
| Q36846855 | Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy |
| Q35860976 | Sequences regulating tropism of human immunodeficiency virus type 1 for brain capillary endothelial cells map to a unique region on the viral genome. |
| Q40912943 | Severe mental illness and HIV-related medical and neuropsychiatric sequelae |
| Q44843655 | Silencing the PTEN gene is protective against neuronal death induced by human immunodeficiency virus type 1 Tat. |
| Q44422490 | Similar subcortical pattern of cognitive impairment in AIDS patients with and without dementia |
| Q36950205 | Smoothened Agonist Reduces Human Immunodeficiency Virus Type-1-Induced Blood-Brain Barrier Breakdown in Humanized Mice |
| Q40065929 | Sonic Hedgehog mimetic prevents leukocyte infiltration into the CNS during acute HIV infection |
| Q36231152 | Study to assess the prevalence, nature and extent of cognitive impairment in people living with AIDS. |
| Q35987635 | The Effect of Central Nervous System Penetration Effectiveness of Highly Active Antiretroviral Therapy on Neuropsychological Performance and Neuroimaging in HIV Infected Individuals |
| Q34779837 | The Effects of Age and HIV on Neuropsychological Performance |
| Q30395989 | The Global Security Perspective on the Effects of Executive Cognitive Function on Complex Behavioral Screening Intervention and HIV/AIDS |
| Q43477271 | The HNRC 500--neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. |
| Q28645981 | The National NeuroAIDS Tissue Consortium (NNTC) Database: an integrated database for HIV-related studies |
| Q40431620 | The Pathogenesis of HIV Infections of the Brain |
| Q35848870 | The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer's disease |
| Q39235790 | The chitinases expression is related to Simian Immunodeficiency Virus Encephalitis (SIVE) and in HIV encephalitis (HIVE). |
| Q37199100 | The impact of environmental risk factors on HIV-associated cognitive decline in children |
| Q51931408 | The impact of neuropsychological impairment and depression on health-related quality of life in HIV-infection. |
| Q34667188 | The pathogenesis of HIV-induced dementia. |
| Q34831062 | The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis |
| Q45625929 | The severe combined immunodeficient (SCID) mouse model of human immunodeficiency virus encephalitis: deficits in cognitive function |
| Q37533136 | The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment |
| Q37781306 | Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction |
| Q64068318 | Trajectory of Physical Functioning Among Persons Living With HIV in Nursing Homes |
| Q42203691 | Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics |
| Q48915551 | Trends related to aging and co-occurring disorders in HIV-infected drug users |
| Q34787071 | Understanding pathogenesis and treatment of HIV dementia: a role for magnetic resonance? |
| Q37200962 | Update on HIV-associated neurocognitive disorders |
| Q36740125 | Visuospatial and Attentional Abilities Predict Driving Simulator Performance Among Older HIV-infected Adults |
| Q33937129 | What is the role of the HIV liaison psychiatrist? |
| Q35828301 | White matter abnormalities revealed by diffusion tensor imaging in non-demented and demented HIV+ patients |
| Q50506570 | [Effect of antiretroviral treatment on early electroencephalographic and otoneurologic manifestations in HIV infection and prognostic importance of verified perturbations] |
| Q79748175 | [Hemidystonia secondary to HIV encephalopathy] |
| Q38934773 | gp120 induces cell death in human neuroblastoma cells through the CXCR4 and CCR5 chemokine receptors |
Search more.